July 21, 2025Obesity

Efficacy and Safety of GLP‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Bayesian NMA shows retatrutide achieved superior weight loss in adults, highlighting safety concerns with higher AE risk.

Retatrutide and dual agonists achieved equivalent mean weight loss of -11.0 kg, surpassing GLP-1 receptor agonists' -9.0 kg.
Retatrutide excels in achieving ≥ 15% weight loss with an odds ratio of 54.6, compared to dual agonists and GLP-1RAs.
Type 2 diabetes mellitus negatively impacted weight loss by 4.3 kg for GLP-1RAs and 5.0 kg for dual agonists.
Personalized treatment selection is advised based on patient characteristics to optimize weight loss outcomes.

Sinha et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark